Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Cyticoline in composition complex neuroprotect therapy at optical glaucoma neuropathy

Poster Details

First Author: L. Hasanzade AZERBAIJAN

Co Author(s):    N. Gurbanova   L. Hasanzada   U. Abilova              

Abstract Details

Purpose:

To estimate influence of preparation of Cyticoline in composition neuroprotect therapy at glaucoma neuroparthy.

Setting:

Cyticoline in composition complex neuroprotect therapy at optical glaucoma neuroparthy

Methods:

A compled study is undertaken 40 patients with glaucoma degeneration. Patients divided into two groups. The firstgroup were made by 24 patients, getting base therapy (angioprotect, antioxidants, vasodilators preparations, complex of vitamins and minerals) and additionally preparation of Cyticoline. The second group was made 23 patients, have got only base therapy. Comparative efficiency of treatment of patients are studied with neuroparthyin both groups. Cyticoline appointed as intramuscular injection and in drug form during 1,5-2 months.

Results:

Visual functions increased in 56,7% eye for the patients, of the first group, and on 43,2% for the patients, of the second group. In addition we marked the improvement of light sensitivity from data of perimetry, especially in the first group in 35,1% and in the second group – 24,3%. It should be noted that most efficiency of therapy, was marked in the first group of patients with optical glaucoma neuroparthy.

Conclusions:

Application of preparation of Cyticolin in complex neuroprotect therapy of glaucoma optikoneuropathy causes more expressed effect of renewal of visual functions and peripheral sight as compare to the second group not getting this preparation.

Financial Disclosure:

NONE

Back to Poster listing